DWS ESG Biotech LC
DE0009769976
DWS ESG Biotech LC/ DE0009769976 /
Стоимость чистых активов10.05.2024 |
Изменение-4.7900 |
Тип доходности |
Инвестиционная направленность |
Инвестиционная компания |
280.5500EUR |
-1.68% |
reinvestment |
Equity
Worldwide
|
DWS Investment GmbH ▶ |
Инвестиционная стратегия
The fund is actively managed. The fund is not managed in reference to a benchmark. The fund promotes environmental and social characteristics and is subject to the disclosure requirements of a financial product in accordance with article 8(1) of Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector. More ESG information is available in the sales prospectus and on the DWS website. The objective of the investment policy is to achieve sustained capital appreciation that exceeds the benchmark (No benchmark).
To achieve this, the fund invests mainly in equities of international companies whose revenues or earnings, as reported in the most recent annual report or other suitable documents of the company, were generated primarily from the biotechnology sector, or whose expenditure was primarily on this sector. Equities of issuers from the health care sector may also be added. When selecting the suitable investments, environmental and social aspects as well as the principles of corporate governance ("ESG standards") are of key importance for the implementation of the fund"s sustainable investment strategy.
Инвестиционная цель
The fund is actively managed. The fund is not managed in reference to a benchmark. The fund promotes environmental and social characteristics and is subject to the disclosure requirements of a financial product in accordance with article 8(1) of Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector. More ESG information is available in the sales prospectus and on the DWS website. The objective of the investment policy is to achieve sustained capital appreciation that exceeds the benchmark (No benchmark).
Основные данные
Тип доходности: |
reinvestment |
Категории фондов: |
Equity |
Регион: |
Worldwide |
Branch: |
Sector Biotechnology |
Бенчмарк: |
- |
Начало рабочего (бизнес) года: |
01.10 |
Last Distribution: |
02.01.2018 |
Депозитарный банк: |
State Street Bank International GmbH |
Место жительства фонда: |
Germany |
Разрешение на распространение: |
Austria, Germany |
Управляющий фондом: |
Dr. Noushin Irani |
Объем фонда: |
364.61 млн
EUR
|
Дата запуска: |
16.08.1999 |
Инвестиционная направленность: |
- |
Условия
Эмиссионная надбавка: |
5.00% |
Max. Administration Fee: |
1.30% |
Минимальное вложение: |
0.00 EUR |
Deposit fees: |
- |
Комиссионные, взимаемые фондами взаимных инвестиций при погашении акций: |
0.00% |
Упрощенный проспект: |
Скачать (Версия для печати) |
Инвестиционная компания
Товарищества на вере: |
DWS Investment GmbH |
Адрес: |
Mainzer Landstraße 11-17, 60329, Frankfurt am Main |
Страна: |
Germany |
Интернет: |
www.dws.de
|
Активы
Stocks |
|
93.90% |
Money Market |
|
3.10% |
Cash |
|
3.00% |
Страны
United States of America |
|
82.10% |
Netherlands |
|
4.10% |
Denmark |
|
3.20% |
Germany |
|
1.80% |
United Kingdom |
|
0.70% |
Ireland |
|
0.60% |
Virgin Islands (British) |
|
0.50% |
Canada |
|
0.40% |
Sweden |
|
0.30% |
Switzerland |
|
0.20% |
Другие |
|
6.10% |
Отрасли
Pharma/Biotechnology |
|
89.70% |
Pharma, production |
|
4.30% |
Другие |
|
6.00% |